Stephen Bickston, MD - Virginia Commonwealth University Health System - Professor of Medicine, Director VCUHS Center for IBD

Stephen Bickston

MD

Virginia Commonwealth University Health System

Professor of Medicine, Director VCUHS Center for IBD

Richmond, VA | United States

Main Specialties: Gastroenterology

Additional Specialties: Inflammatory Bowel Diseases

ORCID logohttps://orcid.org/0000-0001-6432-6470


Top Author

Stephen Bickston, MD - Virginia Commonwealth University Health System - Professor of Medicine, Director VCUHS Center for IBD

Stephen Bickston

MD

Introduction

Dr. Bickston graduated from Duke University and earned his medical degree from the University of North Carolina, Chapel Hill. His residency in internal medicine and fellowship in gastroenterology were at Barnes Hospital, Washington University in St. Louis. He then served as a faculty specialist in IBD at the University of Virginia for more than 12 years. Dr. Bickston was recruited to VCU in 2009 to serve as the medical director of the Inflammatory Bowel Disease Practice and to join the leadership of the Division of Gastroenterology, Hepatology and Nutrition. Dr. Bickston’s practice focuses on integrated clinical care for IBD. He has served as principal investigator for cutting-edge clinical trials in IBD since 1995, and has a similar history of participation in research sponsored by the National Institutes of Health for laboratory and clinical studies in these conditions. He has published 30 papers specifically on IBD, authored dozens of chapters for textbooks, and both edited and authored “The Handbook of Inflammatory Bowel Disease,” a textbook published in 2009. He continues to participate in leading-edge clinical research projects in IBD and in collaborating with basic scientists to find the cause and cure of IBD. Along with American specialty societies, he belongs to the European Crohn’s and Colitis Organization (ECCO) and contributes to the IBD Working Group, an international educational resource for the management of IBD. Dr. Bickston has served on the Crohn’s and Colitis Foundation of America’s Clinical Research Alliance for several years, bringing studies of IBD and pregnancy to VCU. Dr. Bickston is on the Executive Board of the American Gastroenterological Association’s Outcomes Registry, a program intended to improve the quality of care in IBD and other digestive conditions.

Growing up in a military family, Dr. Bickston has lived in eight U.S. states and in both Europe and Asia. He is happy to call Virginia home, having spent nearly 20 years in the commonwealth. He lives in Midlothian, Va., with his wife and two daughters.

Primary Affiliation: Virginia Commonwealth University Health System - Richmond, VA , United States

Specialties:

Additional Specialties:

Research Interests:


View Stephen Bickston’s Resume / CV

Education

Jun 1995
Washington University
Gastroenterology
WUSTL School of Medicine
Jun 1991
Washington University
Internal Medicine
WUSTL School of Medicine
Aug 1984 - May 1988
University of North Carolina
MD
School of Medicine
Aug 1980 - May 1984
Duke University
BS Zoology
Trinity

Experience

Aug 1995 - Dec 2008
University of Virginia Hospital
Faculty, Director of Center for IBD
DOIM-Gastroenterology
Jan 2009
Virginia Commonwealth University Health System
Professor of Medicine, Director VCUHS Center for IBD
DOIM Gastroenterology

Publications

31Publications

376Reads

-Profile Views

How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients.

Inflamm Bowel Dis 2016 May;22(5):1219-30

*Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, Virginia; and †Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MIB.0000000000000685DOI Listing
May 2016
5 Reads
4.464 Impact Factor

Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.

Inflamm Bowel Dis 2015 May;21(5):1151-9

*Robarts Clinical Trials, Robarts Research Institute, Western University, London, ON, Canada; †Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; ‡Center for Inflammatory Bowel Diseases, Richmond, Virginia; §UVA Digestive Health Center of Excellence, University of Virginia Health Systems, Charlottesville, Virginia; and ‖Carolinas Medical Center, University of North Carolina Charlotte Campus, Charlotte, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MIB.0000000000000396DOI Listing
May 2015
62 Reads
4.464 Impact Factor

Endoscopic Evaluation of Microscopic Colitis.

Gastroenterol Hepatol (N Y) 2015 Apr;11(4):262-4

Professor of Internal Medicine Medical Director, Center for Inflammatory Bowel Disease Virginia Commonwealth University Health System Richmond, Virginia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836597PMC
April 2015
6 Reads

Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?

Inflamm Bowel Dis 2014 Nov;20(11):2132-41

*Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom; †Robarts Clinical Trials, Inc., San Diego, California; ‡Division of Gastroenterology, University of California San Diego, La Jolla, California; §Center for Inflammatory Bowel Diseases, Virginia Commonwealth University Health System, Richmond, Virginia; ‖Division of Gastroenterology, Department of Medicine, The University of Western Ontario, London, ON, Canada; ¶Robarts Clinical Trials Inc., Robarts Research Institute, The University of Western Ontario, London, ON, Canada and **Departments of Medicine and Epidemiology and Biostatistics, The University of Western Ontario, London, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MIB.0000000000000218DOI Listing
November 2014
29 Reads
4.464 Impact Factor

Vedolizumab for induction and maintenance of remission in ulcerative colitis.

Cochrane Database Syst Rev 2014 Aug 8(8):CD007571. Epub 2014 Aug 8.

Center for Inflammatory Bowel Diseases, Virginia Commonwealth University Health System Box 980341, Richmond, VA, USA, 23298.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD007571.pub2DOI Listing
August 2014
79 Reads

Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial.

Clin Exp Gastroenterol 2013 Aug 30;6:153-60. Epub 2013 Aug 30.

VCUHS Center for Inflammatory Bowel Disease, Virginia Commonwealth University Health Center, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEG.S35163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770493PMC
August 2013
25 Reads

Tetomilast: new promise for phosphodiesterase-4 inhibitors?

Expert Opin Investig Drugs 2012 Dec 8;21(12):1845-9. Epub 2012 Oct 8.

Virginia Commonwealth University Medical Center, VCUHS Center for Inflammatory Bowel Disease, MCV Campus, Box 980341, Richmond, VA 23298-0341, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.732065DOI Listing
December 2012
4 Reads
5.528 Impact Factor

Natalizumab for the treatment of Crohn's disease.

Expert Rev Clin Immunol 2010 Jul;6(4):513-9

Virginia Commonwealth University Health Center, Box 980341, Richmond, VA 23298-0341, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eci.10.38DOI Listing
July 2010
6 Reads
3.342 Impact Factor

Gastric heterotopia of the rectum.

J Pediatr Gastroenterol Nutr 2010 Mar;50(3):329-33

Division of Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Children's Hospital of Atlanta, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPG.0b013e3181a1c476DOI Listing
March 2010
7 Reads
2.625 Impact Factor

Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.

Cochrane Database Syst Rev 2009 Jan 21(1):CD007571. Epub 2009 Jan 21.

UVA Digestive Health Center of Excellence, University of Virginia Health Systems, 800708 UVAHS, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD007571
Publisher Site
http://dx.doi.org/10.1002/14651858.CD007571DOI Listing
January 2009
5 Reads

Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.

J Manag Care Pharm 2008 May;14(4):352-62

University of Virginia Health System, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2008.14.4.352DOI Listing
May 2008
10 Reads
2.713 Impact Factor

Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.

Inflamm Bowel Dis 2007 Oct;13(10):1250-5

University of North Carolina, Chapel Hill, North Carolina 27599-7032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ibd.20187DOI Listing
October 2007
10 Reads
4.464 Impact Factor

Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis.

Curr Treat Options Gastroenterol 2007 Jun;10(3):171-7

Stephen J. Bickston, MD University of Virginia Digestive Health Center of Excellence, 800708 UVAHS, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11938-007-0010-6DOI Listing
June 2007
8 Reads

Infliximab for ulcerative colitis induction of remission and maintenance therapy.

Gastroenterol Hepatol (N Y) 2007 Jan;3(1):55-6

Associate Professor of Medicine Associate Chief, Division of Gastroenterology & Hepatology Medical Director, Clinical Program in IBD University of Virginia Digestive Health Center of Excellence.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096120PMC
January 2007
4 Reads

Infliximab use in luminal Crohn's disease.

Gastroenterol Clin North Am 2006 Dec;35(4):775-93

Digestive Health Center of Excellence, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gtc.2006.09.003DOI Listing
December 2006
6 Reads
2.824 Impact Factor

Best practices: academic gastroenterology practices.

Clin Gastroenterol Hepatol 2006 Nov;4(11):1415-8

Division of Gastroenterology & Hepatology, UVA Health System, Charlottesville, Virginia 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2006.09.001DOI Listing
November 2006
7 Reads
7.896 Impact Factor

Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?

Clin Gastroenterol Hepatol 2006 Sep 10;4(9):1135-42. Epub 2006 Jul 10.

Division of Gastroenterology & Hepatology, University of Virginia Health System, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2006.05.003DOI Listing
September 2006
4 Reads
7.896 Impact Factor

Evidence-based medications for the treatment of the inflammatory bowel diseases.

Curr Opin Gastroenterol 2006 Jul;22(4):365-9

Digestive Health Center of Excellence, University of Virginia Health System, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mog.0000231809.10773.c7DOI Listing
July 2006
4 Reads
4.289 Impact Factor

Medical management of Crohn's disease: current therapy and recent advances.

Expert Rev Clin Immunol 2006 Jan;2(1):109-20

University of Virginia, Digestive Health Center of Excellence, Division of Gastroenterology & Hepatology, Box 800708, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/1744666X.2.1.109DOI Listing
January 2006
10 Reads
3.342 Impact Factor

Prospective evaluation of pancreatic sphincterotomy as a precut technique for biliary cannulation.

Clin Gastroenterol Hepatol 2004 Nov;2(11):971-7

Digestive Health Center of Excellence, University of Virginia Health System, Charlottesville, Virginia 22908-0708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1542-3565(04)00484-7DOI Listing
November 2004
6 Reads
7.896 Impact Factor

Treatment of luminal and fistulizing Crohn's disease with infliximab.

Gastroenterol Clin North Am 2004 Jun;33(2):387-406, xi

University of Virginia Digestive Health Center of Excellence, Box 800708, UVA Health System, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gtc.2004.02.014DOI Listing
June 2004
4 Reads
2.824 Impact Factor

Future therapies for inflammatory bowel disease.

Curr Gastroenterol Rep 2003 Dec;5(6):518-23

University of Virginia Digestive Health Center of Excellence (UVA-DHCOE), MSB-2nd floor, Room 2121, Charlottesville, VA 22908-0708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11894-003-0043-5DOI Listing
December 2003
5 Reads

Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: a case series and review of pathophysiology.

Dig Dis Sci 2003 Oct;48(10):1960-7

Digestive Health Center of Excellence, University of Virginia Health System, Charlottesville, Virginia 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1026118320460DOI Listing
October 2003
3 Reads
2.550 Impact Factor

Image of the month. Bourne test, enterovesical fistulas.

Gastroenterology 2003 Aug;125(2):291, 641

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0016-5085(03)00959-4DOI Listing
August 2003
3 Reads
16.716 Impact Factor

Keeping the M in mind: recombinant human GMCSF and Crohn's disease.

Inflamm Bowel Dis 2003 Mar;9(2):132

Digestive Health Center of Excellence, University of Virginia, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00054725-200303000-00011DOI Listing
March 2003
5 Reads
4.464 Impact Factor

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.

Liver Transpl 2003 Feb;9(2):138-43

Division of Gastroenterology and Hepatology, The University of Virginia, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/jlts.2003.50017DOI Listing
February 2003
8 Reads
4.241 Impact Factor

Optimal dosing of 5-aminosalicylic acid: 5 decades of choosing between politicians.

Clin Gastroenterol Hepatol 2003 Jan;1(1):3-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/jcgh.2003.50001DOI Listing
January 2003
4 Reads
7.896 Impact Factor

Intestinal ischemia and peripheral gangrene in a patient with chronic renal failure.

Gastroenterology 2002 Feb;122(2):495-9

Digestive Health Center of Excellence, University of Virginia, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/gast.2002.31387DOI Listing
February 2002
13 Reads
16.716 Impact Factor